McKesson
MCK

McKesson (MCK) news

Recent news

Biocon's Shaw: Looking to develop new patented biologics

Biologics by McKesson, a specialty pharmacy division of McKesson Corporation, has established itself as a key player in the delivery of complex therapies for patients with chronic and rare diseases. With over 30 years of experience in the field, the company has developed a robust infrastructure to…

AInvest Wire · 2d ago

S&P places option care health RTGS on watch neg on acqstn

S&P Global has placed Option Care Health’s long-term debt on negative credit watch following reports of a potential acquisition by McKesson and Clayton Dubilier & Rice (CD&R) in a deal valued at over $5 billion, including debt. The move reflects concerns about how the acquisition may affect the…

AInvest Wire · 6d ago

Moody's Ratings places Option Care Health's ratings on review for downgrade following LBO announcement

Moody's Ratings has placed Option Care Health's credit ratings on review for a potential downgrade following the announcement of a leveraged buyout (LBO) by a consortium led by private equity firm Carlyle Group (CD&R) and McKesson Corporation . The transaction, valued at approximately $5.8 billion,…

AInvest Wire · 7d ago

Option Care Health Inc: JP Morgan cuts to neutral from overweight

On October 7, 2026, JPMorgan downgraded Option Care Health Inc. (OPCH) from "Overweight" to "Neutral," marking a shift in its recommendation . This move follows a series of analyst actions over the past several months, including similar downgrades from Jefferies , Barrington Research, and Deutsche…

AInvest Wire · Oct 7, 2026

Option Care Health Inc: Truist Securities cuts to hold from buy; raises target price to $32.05 from $30

Truist Securities has revised its rating for Option Care Health Inc. (OPCH), downgrading the stock from "Buy" to "Hold," while simultaneously raising its price target to $32.05 from $30. This adjustment comes amid ongoing developments in the company’s corporate structure, including a recently…

AInvest Wire · Oct 7, 2026

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.